Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In a report released today, Jason Zemansky from Bank of America Securities maintained a Buy rating on Acumen Pharmaceuticals (ABOS – ...

Urogen's UGN-102 presents a $5B market opportunity for bladder cancer treatment, despite risks. Read more about URGN stock ...

Ruiz covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Cytokinetics, and Lantheus. ARS Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target ...

The health-tech industry’s long-term growth is fueled by the growing need for cutting-edge technologies to address critical ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

In the wake of the presidential election, another change in interest rates and continued news about geopolitical unrest, the appeal of blue-chip stocks is stronger than ever. That' ...

This article highlights 10 affordable healthcare stocks that investors might consider adding to their portfolios. Each of ...